The immunotherapy developer plans to go public in the United States having raised $565m from investors including Eli Lilly and WuXi AppTec.

Cambrian Biopharma is the largest investor in cancer immunotherapy developer Sensei Biotherapeutics, which has filed to raise up to $100m.

Biohaven has purchased the 58% stake cancer immunotherapy developer Kleo Pharmaceuticals it did not already own.

Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.

Klingel subsidiary K-Invest is set to exit the online content analysis tool provider in a purchase of undisclosed size by peer Unicepta.

The drama content producer, which counts iQiyi among its investors, has gone public in Hong Kong and seen its share price rise 84% on its first day of trading.

The stem cell therapy developer has filed to go public seven months after closing $700m in funding from investors including Alphabet unit GV.

Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.

Advance Publications, Cisco, Intel, Fortinet and VMWare have exited the cloud security technology producer in a purchase by Entrust.

WPP has exited the television and video analytics provider in an acquisition by iSpot, with CEO Peter Daboll to become the latter's chief strategy officer.